Senseonics Holdings Inc. (SENS) experienced a 9.2% pre-market plunge on Tuesday, following the release of its fourth quarter and full-year 2024 financial results. While the medical technology company reported a modest increase in revenue, its widening net losses appeared to disappoint investors.
For the full year 2024, Senseonics reported a net loss of $78.6 million, or $0.12 per share, a significant increase from the net loss of $60.4 million, or $0.11 per share, in 2023. The company cited a reduction in gains due to the exchange of outstanding convertible notes and changes in the fair value of derivatives as contributing factors to the widening losses.
Despite the revenue growth, with Q4 revenue reaching $8.3 million and full-year revenue of $22.5 million, the company's mounting losses appear to have overshadowed the positive news, leading to a sell-off in the pre-market trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.